Ameriprise Financial Inc. lessened its stake in GlaxoSmithKline PLC (NYSE:GSK) by 53.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,732,508 shares of the pharmaceutical company’s stock after selling 1,980,522 shares during the quarter. Ameriprise Financial Inc. owned 0.07% of GlaxoSmithKline PLC worth $74,756,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of GSK. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of GlaxoSmithKline PLC by 45.4% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 753 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in shares of GlaxoSmithKline PLC by 1,747.4% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 2,359 shares during the period. Proficio Capital Partners LLC lifted its holdings in shares of GlaxoSmithKline PLC by 233.0% in the 1st quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock valued at $122,000 after buying an additional 1,990 shares during the period. Heritage Trust Co acquired a new position in shares of GlaxoSmithKline PLC in the 1st quarter valued at about $123,000. Finally, Westwood Holdings Group Inc. lifted its holdings in shares of GlaxoSmithKline PLC by 15.7% in the 1st quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock valued at $124,000 after buying an additional 400 shares during the period. 9.28% of the stock is owned by institutional investors and hedge funds.

WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/19/glaxosmithkline-plc-gsk-shares-sold-by-ameriprise-financial-inc.html.

Several equities analysts have recently issued reports on GSK shares. BidaskClub raised GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 13th. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Tuesday, July 18th. Morgan Stanley cut GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a report on Friday, September 8th. Finally, Argus reissued a “buy” rating and issued a $50.00 price objective on shares of GlaxoSmithKline PLC in a report on Thursday, August 31st. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. GlaxoSmithKline PLC has an average rating of “Hold” and an average target price of $46.00.

GlaxoSmithKline PLC (NYSE GSK) opened at 40.05 on Tuesday. The company has a 50-day moving average price of $39.78 and a 200-day moving average price of $41.76. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.54. The firm has a market cap of $97.88 billion, a PE ratio of 39.58 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. The firm had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. On average, equities analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be given a $0.491 dividend. The ex-dividend date is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 4.90%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 197.00%.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.